ClinicalTrials.gg
RecruitingNCT06273826Updated Feb 23, 2024

"Colorectal Leakage App" for Early Detection of Anastomotic Leakage After Colorectal Surgeries

An observational study in Anastomotic Leak Large Intestine and Anastomotic Leak Rectum, sponsored by National Research Oncology and Transplantology Center, Kazakhstan. Recruiting at 1 site in Kazakhstan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by National Research Oncology and Transplantology Center, Kazakhstan · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this prospective observational study is to evaluate the effectiveness of the mobile application "Colorectal Leakage App" in the early diagnosis of anastomotic leakage after colorectal surgeries at the National Research Oncology Center in Astana, Kazakhstan.

Main Questions:

  1. Development, validation, and implementation of the mobile application "Colorectal Leakage App," based on the Dutch Leakage Score.
  2. Evaluate the diagnostic effectiveness of the application in detecting anastomotic leakage after colorectal surgeries.
  3. Determine the frequency of anastomotic leakage after colorectal surgeries performed in the colorectal surgery sector of the National Research Oncology Center in the Astana city.

Participants in the study, individuals aged 18 and above undergoing colorectal surgeries, will be monitored by the mobile application "Colorectal Leakage App" in the postoperative period for early identification of anastomotic leakage.

Read the detailed description

Colorectal cancer ranks third among oncological diseases in Kazakhstan, both in men and women. Anastomotic leakage (AL) following colorectal surgeries is one of the most serious complications arising from colorectal surgical interventions. This condition is characterized by increased mortality and significant deterioration in the quality of life of patients. Additionally, the presence of AL after anterior resections for rectal cancer is associated with an increased risk of local disease recurrence. The frequency of AL varies between 2 and 19%, depending on risk factors, AL definition, and the level of anastomosis. Given the high likelihood and severe consequences of AL, a relevant task is its early detection and effective treatment.

Clinical signs of AL traditionally include fever, tachycardia, pain syndrome, purulent or fecal discharge through drainage, and dynamic bowel obstruction. These signs, combined with other clinical data, are integrated into a diagnostic-specific indicator known as the Dutch Leakage Score (DLS). This indicator is used as a standardized postoperative monitoring protocol for patients suspected of having AL, aiming to minimize delays in detecting this complication and, consequently, reduce early postoperative mortality.

In this prospective observational study, we aim to assess the effectiveness of the mobile application "Colorectal Leakage App" in the early detection of anastomotic leakage (AL) after colorectal surgeries. The study will be conducted at the National Research Oncology Center (NROC) in Astana, Kazakhstan, over one year. The primary goal is to evaluate the diagnostic effectiveness of the application in detecting AL after colorectal surgeries.

It is important to note that there is currently no up-to-date data on the number of colorectal cancer surgeries performed, and information on the frequency of AL after colorectal surgeries in the population of Kazakhstan is also lacking. Previous studies have shown that the effectiveness of the DLS algorithm is directly proportional to the frequency of AL. Therefore, it is assumed that the application of DLS may demonstrate different results in the conditions of Kazakhstan, which we also plan to measure through the "Colorectal Leakage App" mobile application.

  1. Design of the study:

    Prospective observational study, where the "Colorectal Leakage App" mobile application will be implemented in daily postoperative monitoring. Additionally, an assessment of the diagnostic effectiveness of this application will be conducted.

  2. Instruments and equipment:

The "Colorectal Leakage App" is a mobile application that, based on an algorithm, provides an assessment of the risk of Anastomotic Leakage (AL) in patients after colorectal surgeries. The algorithm is built on the standardized postoperative monitoring protocol called "Dutch Leakage Score". After calculating the scores, the application provides recommendations for further actions.

Primary endpoints:

  1. Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value.
  2. Frequency of AL after colorectal surgeries

Secondary endpoints:

  1. Mortality within 30 days:.
  2. Delay in the diagnosis of AL (number of days from the onset of the first signs of a leakage to the diagnosis of AL)
  3. Duration of hospital stay.
  4. Number of days in the ICU.
  5. Number of days between surgery and detection of AL.

Postoperative monitoring with the "Colorectal Leakage App":

It is planned to implement standardized postoperative monitoring for patients who have undergone colorectal surgeries using the "Colorectal Leakage App." The application will include an algorithm based on the Dutch Leakage Score indicator. Each postoperative day, data entry at the patient's bedside will be carried out in the application.

  1. Fever
  2. Heart rate
  3. Respiratory rate
  4. Urinary production
  5. Mental status
  6. Clinical condition
  7. Signs of ileus
  8. Gastric retention
  9. Fascial dehiscence
  10. Abdominal pain, other than
  11. wound pain
  12. Increased leukocyte count, C-reactive protein (CRP), creatinine, and urea.
  13. Nutritional status Based on the data analysis, the algorithm will provide recommendations regarding the necessity of conducting a computer tomography with rectal contrast.

The following information will also be collected: Preoperative risk factors for AL(age, gender, obesity, nutritional status, diabetes, cardiovascular diseases, renal insufficiency, inflammatory bowel diseases, ASAscore, bowel preparation); Surgery data (access, surgery type, anastomosis technique, duration of surgery, blood loss volume, formation of a preventive stoma, intraoperative and postoperative complications, pTNM).

Key points determining the conclusion of a patient's participation in the study will be: the detection of AL, patient discharge from the hospital, or patient death.

02

Conditions studied

  • Anastomotic Leak Large Intestine
  • Anastomotic Leak Rectum

Browse trials for

Keywords

  • Anastomotic Leak
  • Colorectal surgery
  • Mobile application
  • Dutch Leakage Score
03

In context

Anastomotic Leak

240 studies on the registry are indexed under Anastomotic Leak; 72 are open to participants now.

This study's planned enrollment of 120 is below the median of 166 across 111 observational studies indexed under Anastomotic Leak.

Browse Anastomotic Leak studies →

Lead sponsor

National Research Oncology and Transplantology Center, Kazakhstan is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Scheduled patients with benign and malignant colorectal diseases undergoing surgical treatment, including the creation of anastomoses (ileocolic, colocolic, colorectal anastomoses), with or without a preventive stoma.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Scheduled patients with benign and malignant colorectal diseases undergoing surgical treatment, including the creation of anastomoses (ileocolic, colocolic, colorectal anastomoses), with or without a preventive stoma.
  2. Male and female patients aged 18 years and older.
  3. = 0-2; 6. Satisfactory hematological indicators and parameters of liver and kidney function.

Exclusion criteria

Exclusion Criteria:

  1. Participants under 18 years old.
  2. Pregnant, lactating, or planning pregnancy participants.
  3. >2;
  4. Unresctable tumors.
  5. Patient's refusal to continue participating in the study..
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Colorectal Leakage App group

    This group comprises patients who will be monitored using the "Colorectal Leakage App" based on the Dutch leakage score for early detection of anastomotic insufficiency after colorectal surgeries.

    Diagnostic Test: "Colorectal Leakage App"

Interventions

  • Diagnostic test"Colorectal Leakage App"

    The "Colorectal Leakage App" is a mobile application designed to aid in the early detection of anastomotic insufficiency after colorectal surgeries. The app is based on the Dutch Leakage Score (DLS) algorithm, which is a standardized protocol for postoperative monitoring.

06

What researchers measure

Primary outcomes

  1. Diagnostic effectiveness of "Colorectal Leakage App".

    Measurement of sensitivity, specificity, positive predictive value and negative predictive value of the mobile application "Colorectal Leakage App".

    Time frame: 1 year

  2. Frequency of anastomotic leakage after colorectal surgeries.

    Measurement of frequency of anastomotic leakage after colorectal surgeries at the National Research Oncology Center (NROC) in Astana, Kazakhstan.

    Time frame: 1 year

Secondary outcomes

  1. Mortality within 30 days

    Mortality within 30 days

    Time frame: 1 year

  2. Delay in the diagnosis of anastomotic leakage

    Number of days from the onset of the first signs of a leakage to the diagnosis of anastomotic leakage..

    Time frame: 1 year

  3. Duration of hospital stay.

    Duration of hospital stay.

    Time frame: 1 year

  4. Number of days in the ICU.

    Number of days in the ICU.

    Time frame: 1 year

  5. Number of days between surgery and detection of AL.

    Number of days between surgery and detection of AL.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Jutesten H, Buchwald PL, Angenete E, Rutegard M, Lydrup ML. High Risk of Low Anterior Resection Syndrome in Long-term Follow-up After Anastomotic Leakage in Anterior Resection for Rectal Cancer. Dis Colon Rectum. 2022 Oct 1;65(10):1264-1273. doi: 10.1097/DCR.0000000000002334. Epub 2021 Dec 15. PubMed 35482994 ↗
  • Mirnezami A, Mirnezami R, Chandrakumaran K, Sasapu K, Sagar P, Finan P. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. 2011 May;253(5):890-9. doi: 10.1097/SLA.0b013e3182128929. PubMed 21394013 ↗
  • Akasu T, Takawa M, Yamamoto S, Yamaguchi T, Fujita S, Moriya Y. Risk factors for anastomotic leakage following intersphincteric resection for very low rectal adenocarcinoma. J Gastrointest Surg. 2010 Jan;14(1):104-11. doi: 10.1007/s11605-009-1067-4. Epub 2009 Oct 20. PubMed 19841989 ↗
  • Thornton M, Joshi H, Vimalachandran C, Heath R, Carter P, Gur U, Rooney P. Management and outcome of colorectal anastomotic leaks. Int J Colorectal Dis. 2011 Mar;26(3):313-20. doi: 10.1007/s00384-010-1094-3. Epub 2010 Nov 25. PubMed 21107847 ↗
  • Kang CY, Halabi WJ, Chaudhry OO, Nguyen V, Pigazzi A, Carmichael JC, Mills S, Stamos MJ. Risk factors for anastomotic leakage after anterior resection for rectal cancer. JAMA Surg. 2013 Jan;148(1):65-71. doi: 10.1001/2013.jamasurg.2. PubMed 22986932 ↗
  • Boccola MA, Lin J, Rozen WM, Ho YH. Reducing anastomotic leakage in oncologic colorectal surgery: an evidence-based review. Anticancer Res. 2010 Feb;30(2):601-7. PubMed 20332477 ↗
  • Kingham TP, Pachter HL. Colonic anastomotic leak: risk factors, diagnosis, and treatment. J Am Coll Surg. 2009 Feb;208(2):269-78. doi: 10.1016/j.jamcollsurg.2008.10.015. Epub 2008 Dec 4. No abstract available. PubMed 19228539 ↗
  • den Dulk M, Noter SL, Hendriks ER, Brouwers MA, van der Vlies CH, Oostenbroek RJ, Menon AG, Steup WH, van de Velde CJ. Improved diagnosis and treatment of anastomotic leakage after colorectal surgery. Eur J Surg Oncol. 2009 Apr;35(4):420-6. doi: 10.1016/j.ejso.2008.04.009. Epub 2008 Jun 27. PubMed 18585889 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2025, 12 months after the start.

Of 50 non-industry observational studies under Anastomotic Leak, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 73. This study's planned 12 months is below that.

Counting every sponsor, half of 52 studies reached it within 33 months; a quarter within 23 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2024
First posted
Feb 23, 2024
StartActual
Jan 19, 2024
Primary completionEst.
Jan 2025
CompletionEst.
May 2025
Last update
Feb 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06273826
Lead sponsor
National Research Oncology and Transplantology Center, Kazakhstan
Responsible party
Meiram Mamlin, MD (Head of the colorectal division., National Research Oncology and Transplantology Center, Kazakhstan) — Principal investigator
First posted
Feb 23, 2024
Start date
Jan 19, 2024
Primary completion
Jan 2025 (estimated)
Completion
May 2025 (estimated)
Last update
Feb 23, 2024

Study contacts

Saule Khamzina, MD
Contact
khamzina.saule88@gmail.com
+77757172961
Arman Kozhakhmetov, MD
Contact
a.kozhakhmetov@nu.edu.kz
+77772714801
Meiram Mamlin, MD
principal investigator · National Research Oncology Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion